Back to Search
Start Over
An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil
- Source :
- Pulmonary pharmacologytherapeutics. 66
- Publication Year :
- 2020
-
Abstract
- Treprostinil, a prostacyclin analogue used in the treatment of pulmonary arterial hypertension (PAH), is available for administration by parenteral, oral, or inhaled routes. Transitioning between routes may be beneficial for appropriate patients; however, there is little published data on transitions between oral and inhaled treprostinil. We used a modified Delphi process to develop expert consensus recommendations on transitions between these formulations. Three questionnaires were used to develop statements about relevant aspects of transition management, which the panelists rated, using a Likert scale, from -5 (strongly disagree) to +5 (strongly agree). Eleven physicians with expertise in PAH treatment modalities, participated in the panel. Of the 492 statements evaluated, consensus was reached on 215 (43.7%). Key consensus recommendations included (1) accurately defining successful transition, as stable or improved PAH with good tolerability and adherence, and (2) patients with stable, low-risk PAH showing insufficient response or tolerability to their existing treprostinil therapy (and due to restrictions in up titration of dosing), as appropriate candidates for transitions between treprostinil formulations. Panelists did not reach consensus for an overall strategy for performing these transitions, mainly because of variability in their practice parameters. Consensus was also achieved on recommendations for adverse event management, including reassurance, administration of oral treprostinil 3 times daily with food, and dosing inhaled treprostinil at intervals ≥3 hours apart. The Delphi process aided in developing expert consensus recommendations that may provide clinically useful guidance for transitioning between treprostinil formulations. However, additional data from centers with high volumes of PAH patients undergoing treprostinil transitions would be optimal for defining more complete and robust strategies to facilitate successful transition.
- Subjects :
- Pulmonary and Respiratory Medicine
medicine.medical_specialty
Consensus
Delphi Technique
Hypertension, Pulmonary
Delphi method
Modified delphi
Administration, Oral
03 medical and health sciences
0302 clinical medicine
Administration, Inhalation
medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
Dosing
Intensive care medicine
Adverse effect
Antihypertensive Agents
computer.programming_language
business.industry
Patient Selection
digestive, oral, and skin physiology
Biochemistry (medical)
Epoprostenol
030228 respiratory system
Tolerability
Treatment modality
business
computer
Delphi
Treprostinil
medicine.drug
Subjects
Details
- ISSN :
- 15229629
- Volume :
- 66
- Database :
- OpenAIRE
- Journal :
- Pulmonary pharmacologytherapeutics
- Accession number :
- edsair.doi.dedup.....bfb25bc7b9ea062f8269344a571da289